Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Schaerbeek – page 30

1 961 clinical trials in Schaerbeek, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Schaerbeek at a glance
1 961
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 961 trials in Schaerbeek

Open in trial search

Study of plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Study of Lutetium-177-PSMA treatment for patients with advanced clear cell kidney cancer who had progression after first or second line therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Asthma

Recruiting

Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.

Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Prednisolone Acetate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Basilea Pharmaceutica International AG Allschwil

Study of cefadroxil effectiveness in adult patients with Staphylococcus aureus bloodstream infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cefadroxil
  • Sponsor:UZ Brussel

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Schaerbeek

What the registry says about research in the country

01 Digestive System Diseases

In Schaerbeek, researchers are focusing on common gastrointestinal complaints such as functional dyspepsia, heartburn and reflux, aiming to improve patient outcomes through medication optimization.

  • Assessing de‑prescribing strategies for chronic proton pump inhibitors
  • Comparing on‑demand use versus alginate‑based alternatives
  • Evaluating patient‑centered approaches to reduce unnecessary medication

The trials seek to identify safer, effective ways to manage acid‑related disorders while minimizing long‑term drug exposure.

02 Virus Diseases

A parallel study in Schaerbeek targets viral infections of the oral cavity, specifically patients with frequent orofacial herpes infections.

  • Testing the efficacy of the antiviral candidate 2LHERP®
  • Measuring reduction in episode frequency over a 12‑month period
  • Improving quality of life for individuals prone to recurrent outbreaks

The goal is to determine whether the new treatment can significantly lower the number of herpes episodes compared with standard care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.